Skip to main content

hsp90 inhibitor xl888

Generic: Hsp90 Inhibitor XL888

hsp90 inhibitor xl888: 2 clinical trials tracked.

hsp90 inhibitor xl888 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about hsp90 inhibitor xl888, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

MelanomaSkin Cancer

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

Phase Ib Trial of Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Malignancies

NCT03095781Registry updated 2026-05-22·Phase 1
Completed

Primary endpoint: Recommended Phase II Dose of the Combination of XL888 and Pembrolizumab as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

Interventionalopen47 enrolledStarted 2017-07Completion 2021-063 sites · United StatesEmory University

Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

NCT02721459Registry updated 2026-03-02·Phase 1
Active, not recruiting

Primary endpoint: Maximum Tolerated Dose (MTD)

Interventionalopen26 targetStarted 2016-09Completion 2026-111 site · United StatesH. Lee Moffitt Cancer Center and Research Institute